Possible Connection Between Non-Alcoholic Fatty Liver Disease and Type-2 Diabetes Mellitus

Rajdeep  Ghosh; Lakshmi Chakradhar  Yarlagadda; Chaitali  Mondal; Ullash  Basak; Debasish  Ghosh; Aaheli  Rudra; Tejashwi  Paruchuri; Joy Sarkar

doi:10.55489/njcm.151020244418

Authors

Rajdeep Ghosh M.R. Bangur Super Speciality Hospital, Tollygunge, Kolkata, West Bengal, India
Lakshmi Chakradhar Yarlagadda GSL Medical College and General Hospital, Rajahmundry, Andhra Pradesh, India
Chaitali Mondal South DumDum Municipal Hospital, Kolkata, India
Ullash Basak GSL Medical College and General Hospital, Rajahmundry, Andhra Pradesh, India
Debasish Ghosh Health & Family Welfare, Govt of West Bengal, Swasthya Bhawan, Kolkata, India
Aaheli Rudra Jhargram Government Medical College & Hospital, West Bengal, India
Tejashwi Paruchuri GSL Medical College and General Hospital, Rajahmundry, Andhra Pradesh, India
Joy Sarkar Dinabandhu Andrews College, Kolkata, India https://orcid.org/0000-0002-6404-7428

DOI:

https://doi.org/10.55489/njcm.151020244418

Keywords:

NAFLD, Diabetes, Obesity, Glucotoxicity, Insulin Resistance

References

Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol. 2008;24(3):320-7. Doi: https://doi.org/10.1097/MOG.0b013e3282fbccf2

Yamaguchi K, Yang L, McCall S, Huang J, Xing XY, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366-74. Doi: https://doi.org/10.1002/hep.21655

Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol. 2020;6(1). Doi: https://doi.org/10.1186/s40842-020-00097-1

PD C, J A, MA I, M P, C K, D B, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-72. Doi: https://doi.org/10.2337/db06-1491

Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol. 2013;27(1):73-83. Doi: https://doi.org/10.1016/j.bpg.2013.03.007

Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med [Internet]. 2016;8(1). Doi: https://doi.org/10.1186/s13073-016-0303-2

CH K, ZM Y. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75(10):721-8. Doi: https://doi.org/10.3949/ccjm.75.10.721

Gastaldelli A. Fatty liver disease: The hepatic manifestation of metabolic syndrome. Hypertension Research. 2010;33(6):546-7. Doi: https://doi.org/10.1038/hr.2010.60

Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980 Jul;55(7):434-8. PMID: 7382552.

Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. J Hepatol. 2018;68(2):251-67. Doi: https://doi.org/10.1016/j.jhep.2017.11.006

Cusi K. Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes. Diabetes Care. 2020;43(2):275-9. Doi: https://doi.org/10.2337/dci19-0064